R-Tech Ueno, Sucampo, Takeda gastrointestinal news

In March, Sucampo submitted a request for arbitration with the International Chamber of Commerce alleging that Takeda violated the terms of a 2004 deal that granted Takeda rights to market Sucampo's Amitiza lubiprostone in the U.S. and Canada. Sucampo alleged that Takeda's conduct, including its dealings with pharmacy and managed care organization, injured Sucampo and the Amitiza brand. R-Tech, which is responsible for manufacturing and supplying Amitiza under the 2004 deal, submitted an amended and supplemental request for arbitration also alleging that Takeda violated the deal. Takeda and Sucampo now co-promote Amitiza in the U.S. Amitiza had sales of $209.2 million in 2009. ...